

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* CARLSON MARILYN R. (Last) (First) (Middle) C/O EVOKE PHARMA, INC. 420 STEVENS AVENUE, SUITE 370 (Street) SOLANA CA 92075 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Evoke Pharma Inc [EVOK]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Medical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 06/17/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$3.07	06/17/2019		D			50,000	(1)	01/27/2026	Common Stock	50,000	(2)	0	D	
Stock Option (Right to Buy)	\$3.04	06/17/2019		D			75,000	(3)	02/04/2026	Common Stock	75,000	(4)	0	D	
Stock Option (Right to Buy)	\$3.04	06/17/2019		D			33,750	(3)	02/04/2026	Common Stock	33,750	(5)	0	D	
Stock Option (Right to Buy)	\$2.36	06/17/2019		D			100,000	(6)	01/24/2027	Common Stock	100,000	(7)	0	D	
Stock Option (Right to Buy)	\$2.43	06/17/2019		D			125,000	(8)	02/06/2028	Common Stock	125,000	(9)	0	D	
Stock Option (Right to Buy)	\$2.94	06/17/2019		D			125,000	(10)	02/05/2029	Common Stock	125,000	(11)	0	D	
Stock Option (Right to Buy)	\$0.62	06/17/2019		A			37,500	(12)	01/27/2026	Common Stock	37,500	\$0.00	37,500	D	
Stock Option (Right to Buy)	\$0.62	06/17/2019		A			56,250	(12)	02/04/2026	Common Stock	56,250	\$0.00	56,250	D	
Stock Option (Right to Buy)	\$0.62	06/17/2019		A			25,312	(12)	02/04/2026	Common Stock	25,312	\$0.00	25,312	D	
Stock Option (Right to Buy)	\$0.62	06/17/2019		A			75,000	(12)	01/24/2017	Common Stock	75,000	\$0.00	75,000	D	
Stock Option (Right to Buy)	\$0.62	06/17/2019		A			93,750	(12)	02/06/2028	Common Stock	93,750	\$0.00	93,750	D	

